Alkermes ALKS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Aristada And Aristada Initio | $93.82M-3.5% | $97.22M-0.8% | $98.05M-3.2% | $101.3M+37.9% | $73.48M-24.0% | |
| LUMRYZ | $39.49M— | —— | —— | —— | —— | |
| LYBALVI | $92.36M-1.9% | $94.14M-4.2% | $98.25M+16.6% | $84.28M+20.4% | $70.02M-9.0% | |
| Vivitrol | $112.43M-9.4% | $124.13M+2.5% | $121.13M-0.4% | $121.66M+20.5% | $101M-24.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alkermes break its business down?
- Alkermes (ALKS) reports revenue by product across 4 parts — Aristada And Aristada Initio, LUMRYZ, LYBALVI and Vivitrol. Each is extracted from the segment footnotes and tracked over time.
- Where does Alkermes's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alkermes's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
